These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36459954)

  • 1. Durable medication-free remission of sarcoidosis following discontinuation of anti-tumor necrosis factor-α therapy.
    Yee AMF
    Respir Med; 2023 Jan; 206():107055. PubMed ID: 36459954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: A meta-analysis.
    Rezaee M; Zangiabadian M; Soheili A; Calcagno TM; Rahmannia M; Dinparastisaleh R; Nasiri MJ; Mirsaeidi M
    Eur J Intern Med; 2023 Mar; 109():42-49. PubMed ID: 36526497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
    Baughman RP; Lower EE; Drent M
    Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):76-89. PubMed ID: 19382527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
    Casanova MJ; Chaparro M; Nantes Ó; Benítez JM; Rojas-Feria M; Castro-Poceiro J; Huguet JM; Martín-Cardona A; Aicart-Ramos M; Tosca J; Martín-Rodríguez MDM; González-Muñoza C; Mañosa M; Leo-Carnerero E; Lamuela-Calvo LJ; Pérez-Martínez I; Bujanda L; Hinojosa J; Pajares R; Argüelles-Arias F; Pérez-Calle JL; Rodríguez-González GE; Guardiola J; Barreiro-de Acosta M; Gisbert JP;
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1277-1288. PubMed ID: 33962482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases.
    Heidelberger V; Ingen-Housz-Oro S; Marquet A; Mahevas M; Bessis D; Bouillet L; Caux F; Chapelon-Abric C; Debarbieux S; Delaporte E; Duval-Modeste AB; Fain O; Joly P; Marchand-Adam S; Monfort JB; Noël N; Passeron T; Ruivard M; Sarrot-Reynauld F; Verrot D; Bouvry D; Fardet L; Chosidow O; Sève P; Valeyre D
    JAMA Dermatol; 2017 Jul; 153(7):681-685. PubMed ID: 28564695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab for CNS sarcoidosis: single-center experience and literature review.
    Hutto SK; Kyle K; Cavanagh JJ; Reda H; Venna N
    J Neurol; 2022 Apr; 269(4):2064-2072. PubMed ID: 34487233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-α: a treatment target or cause of sarcoidosis?
    Amber KT; Bloom R; Mrowietz U; Hertl M
    J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2104-11. PubMed ID: 26419478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.
    Ben-Horin S; Chowers Y; Ungar B; Kopylov U; Loebstein R; Weiss B; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2015 Aug; 42(3):356-64. PubMed ID: 26032402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup.
    Schmidt J; Kermani TA; Bacani AK; Crowson CS; Matteson EL; Warrington KJ
    Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1079-83. PubMed ID: 22328491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Bohm M; Xu R; Zhang Y; Varma S; Fischer M; Kochhar G; Boland B; Singh S; Hirten R; Ungaro R; Shmidt E; Lasch K; Jairaith V; Hudesman D; Chang S; Lukin D; Swaminath A; Sands BE; Colombel JF; Kane S; Loftus EV; Shen B; Siegel CA; Sandborn WJ; Dulai PS;
    Aliment Pharmacol Ther; 2020 Aug; 52(4):669-681. PubMed ID: 32656800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study.
    Lahmer T; Knopf A; Lanzl I; Heemann U; Thuermel K
    Rheumatol Int; 2012 Aug; 32(8):2367-70. PubMed ID: 21644042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
    Faleck DM; Shmidt E; Huang R; Katta LG; Narula N; Pinotti R; Suarez-Farinas M; Colombel JF
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):238-245.e4. PubMed ID: 32569749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
    Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
    Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.